Hyperkalemia: a modern view on the problem and the potentials for therapy (Part 2)


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The second part of the review presents the methods of treatment of acute and chronic hyperkalemia in patients with impaired renal function (including diet therapy), particular attention is paid to the pathogenetic validity of the use of certain therapeutic measures.

Full Text

Restricted Access

About the authors

N. A Mikhailova

FSBEI FPE "Russian Medical Academy of Continuing Professional Education” of RMH

Email: natmikhailova@mail.ru
PhD in Medical Science, Associate Professor at the Department of Nephrology and Hemodialysis

O. N Kotenko

SBHCI "City Clinical Hospital № 52" of Moscow Healthcare Department

Email: olkotenko@yandex.ru
PhD in Medical Sciences, Chief External Expert-Nephrologist of Moscow Healthcare Department, Deputy Chief Physician for Nephrology SBHCI "CCH № 52 of Moscow Healthcare Department", Associate Professor at the Department of Hospital Therapy with a Course of Hematology FSAEI HE PFUR, President of the Moscow Association of Nephrologists

E. M Shilov

FSAEI HE "First Moscow State Medical University n.a. I.M. Sechenov" of RMH

Doctor of Medical Sciences, Professor, Head of the Department of Nephrology and Hemodialysis

References

  1. Chamberlain M. Emergency treatment of hyperkalaemia. Lancet. 1964;1:464-467.
  2. Levine M., Nikkanen H., Pallin D.J. The effects of intravenous calcium in patients with digoxin toxicity. J. Emerg. Med. 2011;40:41-46.
  3. Ho K. A critically swift response: insulin-stimulated potassium and glucose transport in skeletal muscle. Clin. J. Am. Soc. Nephrol. 2011;6:1513-1516.
  4. DeFronzo R.A., Felig P., Ferrannini E., Wahren J. Effect of graded doses of insulin on splanchnic and peripheral potassium metabolism in man. Am. J. Physiol. 1980;238:E421-427.
  5. Nguyen T.Q., Maalouf N.M., Sakhaee K., Moe O.W. Comparison of insulin action on glucose versus potassium uptake in humans. Clin. J. Am. Soc. Nephrol. 2011;6:1533-1539.
  6. Elliott M.J., Ronksley P.E., Clase C.M., Ahmed S.B., Hemmelgarn B.R. Management of patients with acute hyperkalemia. CMAJ. 2010; 182:1631-1635.
  7. Allon M., Dunlay R., Copkney C. Nebulized albuterol for acute hyperkalemia in patients on hemodialysis. Ann. Intern. Med. 1989;110:426-429.
  8. Palmer B.F. Regulation of potassium homeostasis. Clin. J. Am. Soc. Nephrol. 2015;10:1050-1060.
  9. Iqbal Z., Friedman E.A. Preferred therapy of hyperkalemia in renal insufficiency: survey of nephrology training-program directors. N. Engl. J. Med. 1989;320:60-61.
  10. Gutierrez R., Schlessinger F., Oster J.R., Rietberg B., Perez G.O. Effect of hypertonic versus isotonic sodium bicarbonate on plasma potassium concentration in patients with end-stage renal disease. Miner Electrolyte Metab. 1991;17:297-302.
  11. Greenberg A. Hyperkalemia: treatment options. Semin. Nephrol. 1998;18:46-57.
  12. Kao K.C., Huang C.C., Tsai Y.H., Lin M.C., Tsao T.C. Hyperkalemic cardiac arrest successfully reversed by hemodialysis during cardiopulmonary resuscitation: case report. Chang Gung Med. J. 2000;23:555-559.
  13. Blumberg A., Roser H.W., Zehnder C., Muller-Brand J. Plasma potassium) in patients with terminal renalfailure during and after haemodialysis; relationship with dialytic potassium removal and total body potassium. Nephrol. Dial. Transplant. 1997;12:1629-1634.
  14. Sherman R.A., Mehta O.: Phosphorus and potassium content of enhanced meat and poultry products: implicationsfor patients who receive dialysis. Clin. J. Am. Soc. Nephrol. 2009;4(8):1370-1373.
  15. Sterns R.H., Rojas M., Bernstein P., Chennupati S. Ion-exchange resins for the treatment of hyperkalemia: are they safe and effective? Jam. Soc. Nephrol. 2010;21:733-735.
  16. Harel Z., Harel S., Shah P.S., Wald R., Perl J., Bell C.M. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am. J. Med. 2013;126:264.e9-264.e24.
  17. US Food and Drug Administration. Kayexalate (sodium polystyrene sulfonate) powder: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER) - September 2009. Available at http://wwwfda.gov/ Safety/MedWatch/Safetyinformation/ucm 186845.htm. Accessed September 15;2015
  18. Watson M.A., Baker T.P., Nguyen A., Sebastianelli M.E., Stewart H.L., Oliver D.K., Abbott K.C., Yuan C.M. Association of prescription of oral sodium polystyrene sulfonate with sorbitol in an inpatient setting with colonic necrosis: a retrospective cohort study. Am. J. Kidney. Dis. 2012; 60:409-416.
  19. Ziessman H. Alkalosis and seizure due to a cation-exchange resin and magnesium hydroxide. Southern. Med. J. 1976;69:497-499.
  20. Hirasawa Y. Clinical experience in using Kalimate inpatients with renalfailure. Medical consultations & new remedies. 1973;10:1021-1029.
  21. Suzuki Y., Mimura N. Inhibitory effects of calcium polystyrene sulphonate (Kalimate) on serum potassium values in cases of hyperkalemia accompanying renalfailure. Clinical medicine. 1973;15(12):1794-1806.
  22. Information of adverse drug reaction № 40. Safety Division, Pharmaceutical affairs bureau, Ministry of Health and Welfare. Japan. Dec. 1979.
  23. Minford E.J., Hand T., Jones M.C. Constipation and colonic perforation complicating calcium resonium therapy (Letter to the editor). Postgrad Med J.1992;68(798):302.
  24. Li Xiao, Xu Gang, Lin Hong-li, Hu Zhao, Yu Xue-qing, Xing Chang-ying, Mei Chang-lin, Zuo Li, Ni Zhao-hui, Ding Xiao-qiang, Li De-tian, Chen Nan. Calcium Polystyrene Sulfonate in Treating Hyperkalemia Patients with Chronic Kidney Disease: Multi-center Clinical Study. Chin. J. Nephrol. 2013;29(6):419-422.
  25. Ватазин А.В., Шилов Е.М., Хозяинова Н.Ю. Новые возможности коррекции гиперкалимии у пациентов с хронической болезнью почек. Нефрология. 2016;20:47-53.
  26. Tomino Y.1, Yamazaki T., Shou I., Tsuge T., Satake K., Takeda Y., Ohtani A., Nishitani T., Kurusu A., Hamada C., Horikoshi S., Maeda K., Tanaka Y., Fukuda H., Wakabayashi M., Seto T. Dose-response to a jelly preparation of calcium polystyrene sulfonate in patients with hyperkalemia-changes in serum potassium levels with or without a RAAS inhibitor. Clin. Nephrol. 2007;68(6):379-385.
  27. Yu M.Y., Yeo J.H., Park J.S. Lee C.H., Kim G.H. Long-term efficacy of oral calcium polystyrene sulfonate for hyperkalemia in CKD patients. PLoS One. 2017. Mar. 22;12(3):e0173542.
  28. Einhorn L.M., Zhan M., Hsu V.D., Walker L.D., Moen M.F., Seliger S.L., Weir M.R., Fink J.C. The frequency of hyperkalemia and its significance in chronic kidney disease. Arch. Intern. Med. 2009;169:1156-1162.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies